Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAMUSCULAR, SUBCUTANEOUSStandard

DAXXIFY

DAXIBOTULINUMTOXINA-LANM

Standard Dose
0.1ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview DAXXIFY is listed in Drugs@FDA under application 761127 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient DAXIBOTULINUMTOXINA-LANM Form and strength INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS - 0.1ML Sponsor REVANCE THERAPEUTICS, INC.

Structured Monograph

Clinical summary

Approval overview DAXXIFY is listed in Drugs@FDA under application 761127 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient DAXIBOTULINUMTOXINA-LANM Form and strength INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS - 0.1ML Sponsor REVANCE THERAPEUTICS, INC. Submission history Latest submission status date: 2023-08-11 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.